Komori
Share Issuance and Disposal4599StemRIM Inc.Pharmaceuticals

Notice Regarding the Finalization of the Terms of Stock Options (Share Acquisition Rights) Granted to the Company's Directors

For the stock options for directors approved on 9 September 2026, the previously undetermined total number of share acquisition rights, number of underlying shares, exercise price and allottees have been finalized.

Worth reading
40Recurring
Scored from 3 of 5 sections
Direction
Neutral
Direction inferred from the company’s description.
Scale
300000
Shares
Wording
Definitive
How definitive the wording is.

Details of issuance or disposal

Issuance of stock options (share acquisition rights) to the Company's directors (StemRIM Inc. 20th Series Share Acquisition Rights)

Who receives how much

300,000 shares of the Company's common stock (3,000 share acquisition rights, 100 shares per right)

4 of the Company's directors (breakdown of shares: 非開示)

The lower thin line represents the existing number of shares to which these shares will be added.

Terms of the stock acquisition rights
Exercise price
¥24,500 per share acquisition right (¥245 per share). Whether an adjustment provision applies and the adjustment floor: Not disclosed
Number of Stock Acquisition Rights
Total issuance: 3,000 share acquisition rights. Number of unexercised rights remaining: Not disclosed
Categories and Number of Persons Covered
4 of the Company's directors. Breakdown of shares allocated: Not disclosed
Details of issuance or disposal
ItemDetails
Type of issuance or disposalIssuance of stock options (share acquisition rights) to the Company's directors (StemRIM Inc. 20th Series Share Acquisition Rights)
Number of shares to be issued or disposed of300,000 shares of the Company's common stock (3,000 share acquisition rights, 100 shares per right)
Intended allottee4 of the Company's directors (breakdown of shares: Not disclosed)
Exercise price¥24,500 per share acquisition right (¥245 per share). Whether an adjustment provision applies and the adjustment floor: Not disclosed
Number of Stock Acquisition RightsTotal issuance: 3,000 share acquisition rights. Number of unexercised rights remaining: Not disclosed
Categories and Number of Persons Covered4 of the Company's directors. Breakdown of shares allocated: Not disclosed
Items this document does not state (22)
Issue price and disposal priceTotal issue valueAmount of funds to be raisedEstimated issuance expensesSpecific use of fundsPayment dateIntended allottee's holding policyDilution RateTotal number of issued sharesBasis for determining the amount to be paidExercise periodTransfer restriction periodConditions for lifting transfer restrictionsReason for acquisition without considerationTotal Stock-Based CompensationUnderwriter / lead underwriterOverallotmentStock Split RatioProcedures under the Corporate Code of ConductMost recent equity financingMajor shareholders after the offeringImpact on Business Performance

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

Because the previously undecided matters concerning the stock options approved at the Board of Directors meeting held on 9 September 2026 have been finalized.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice Regarding the Finalization of the Terms of Stock Options (Share Acquisition Rights) Granted to the Company's Directors | StemRIM Inc. (4599) timely disclosure | Komori